Harrow: Former Employees Raise Concerns About Sampling, Rebating Practices for IHEEZO Eye Medication

Published on Aug 27, 2024

Last quarter, emerging branded pharmaceutical company Harrow (HROW) disclosed that unit demand volumes for its ocular anesthetic IHEEZO nearly doubled from the previous quarter up to 30,016 from 15,176 units.

Already have an account? Log in.

This article is currently locked and only available to subscribers. Request a trial to receive unlimited access to all articles.

View Only Unlocked Articles

Copyright ©2024 The Capitol Forum. All Rights Reserved.